Answers are grounded in this paper and cite their sources.
Objectives: Most patients with new-onset refractory status epilepticus (NORSE) subsequently develop drug-resistant epilepsy (DRE) with multiple seizure foci and are not the typical candidates for resective surgery. We report the first case of DRE developing after cryptogenic-NORSE (C-NORSE) that was successfully treated using deep brain stimulation targeting the anterior nucleus of the thalamus (ANT-DBS). Methods: A 52-year-old man developed C-NORSE at the age of 45 years and presented with sequelae of DRE and cognitive dysfunction despite anti-seizure medications and immunotherapy administration. Seizure semiology comprised palpitations, chills, and nausea, followed by impairment of awareness with oral automatism multiple times a day. Video-electroencephalogram monitoring (vEEG) showed bilateral independent electrographic seizures (ESz) in the fronto-temporal areas. He underwent ANT-DBS. Preoperative and postoperative vEEG recordings for 3 days were compared. The patient had not developed an overt clinical seizure until the last follow-up at 9 months. No adverse events were observed during treatment. Conclusion: ANT-DBS is an effective treatment option for DRE after NORSE, particularly when the epileptogenic network is located in the temporal lobe. A detailed evaluation using vEEG is useful for identifying the epileptogenic foci and assessing therapeutic outcome. Immunomodulatory mechanisms via cytokines could play roles in the pathogenesis of development of DRE after NORSE and seizure suppression effect of ANT-DBS.
No takes yet. Share an insight, caveat, or question.
Sasaki et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: